(19)
(11) EP 3 846 894 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
18.06.2025 Bulletin 2025/25

(45) Mention of the grant of the patent:
14.05.2025 Bulletin 2025/20

(21) Application number: 19783669.5

(22) Date of filing: 04.09.2019
(51) International Patent Classification (IPC): 
A61N 1/32(2006.01)
A61N 1/04(2006.01)
 A61N 1/40(2006.01)
(52) Cooperative Patent Classification (CPC):
A61N 1/32; A61N 1/40; A61N 1/36034; A61N 1/0476
(86) International application number:
PCT/IB2019/057452
(87) International publication number:
WO 2020/049482 (12.03.2020 Gazette 2020/11)

(54)

TREATING AUTOIMMUNE DISEASES USING AN ALTERNATING ELECTRIC FIELD TO REDUCE THE PROLIFERATION OF T-CELLS

BEHANDLUNG VON AUTOIMMUNERKRANKUNGEN UNTER VERWENDUNG EINES ELEKTRISCHEN WECHSELFELDS ZUR VERRINGERUNG DER PROLIFERATION VON T-ZELLEN

TRAITEMENT DE MALADIES AUTO-IMMUNES À L'AIDE D'UN CHAMP ÉLECTRIQUE ALTERNATIF POUR RÉDUIRE LA PROLIFÉRATION DE LYMPHOCYTES T

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 07.09.2018 US 201862728174 P

(43) Date of publication of application:
14.07.2021 Bulletin 2021/28

(73) Proprietor: Novocure GmbH
6340 Baar (CH)

(72) Inventors:
  • ALON, Yaniv
    4201663 Netanya (IL)
  • VOLOSHIN-SELA, Tali
    3657900 Kibbutz Gvat (IL)
  • GILADI, Moshe
    40691 Moshav Herut (IL)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)


(56) References cited: : 
JP-A- 2006 167 476
US-A1- 2012 283 726
US-A1- 2018 001 075
 US-A1- 2006 167 499
US-A1- 2017 281 934
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).